Study of medicines for Von Willebrand disease during pregnancy
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Women’s health & pregnancy clinical trials.
This study looks at how well a Von Willebrand disease treatment plan works during pregnancy, and whether some patients need extra “adjusting” of medicine. It may help prevent bleeding problems by matching treatment to each person’s lab results later in pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and have Von Willebrand disease (VWD), such as Type 1, 2, or 3
- You must be able to have blood tests done around weeks 34–38 to check von Willebrand factor and factor VIII levels
- You must sign consent before 39 weeks of pregnancy
- A clinician must think you can safely take Wilate (a VWD medicine) and possibly tranexamic acid
- You must not have certain bleeding/blood/platelet disorders or related collagen disorders
- Your study site must be able to monitor the needed blood tests to adjust Wilate dosing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called Wilate, given regularly (prophylaxis), can reduce heavy menstrual bleeding in women with von Willebrand disease. It compares Wilate to a placebo (a dummy treatment) to see if it helps more than no treatment.
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
This trial tests whether a special algorithm can reduce repeat bleeding from the gut or nose in people with inherited Von Willebrand disease. If you have had serious nosebleeds or digestive bleeding, this study may help find a better way to manage your condition.
Hear when a new Von Willebrand Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.